Roth Capital initiated coverage of Capricor Therapeutics (CAPR) with a Buy rating and $31 price target The firm’s optimism on the shares is driven by “first-in-indication” deramiocel’s ability to improve cardiac and skeletal muscle function in Duchenne muscular dystrophy patients with cardiomyopathy. The firm expects a U.S. launch in Q4, with projected sales of $1B and $3.3B in 2030 and 2038, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics’ Earnings Call: Optimism Amid Challenges
- Capricor Therapeutics: Buy Rating Affirmed Amid Strong Financials and Promising Regulatory Progress for Deramiocel
- Capricor Therapeutics: Promising Developments and Financial Stability Support Buy Rating Amid Upcoming PDUFA Date for Deramiocel
- Capricor Therapeutics Reports Q1 2025 Financial Results
- Closing Bell Movers: Exelixis up 6% on earnings beat